Across TCGA pan-cancer cohorts, USHBP1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated USHBP1 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher USHBP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated USHBP1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
LIHC, SCLC, and SKCM are the cancer types where USHBP1 Mutation most reproducibly stratifies survival.